Safety and Efficacy of Switching a Stable Combined Antiretroviral Therapeutic Regimen to Atazanavir With Ritonavir Plus Lamivudine in Treatment Experienced HIV Positive Patients With Full and Stable Virological Suppression

Trial Profile

Safety and Efficacy of Switching a Stable Combined Antiretroviral Therapeutic Regimen to Atazanavir With Ritonavir Plus Lamivudine in Treatment Experienced HIV Positive Patients With Full and Stable Virological Suppression

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Atazanavir (Primary) ; Lamivudine (Primary) ; Ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ATLAS; ATLAS 2; ATLAS-M
  • Most Recent Events

    • 10 Mar 2017 Results of substudy(n=201) assessing the impact of the atazanavir/ritonavir+lamivudine dual therapy versus the three-drug continuing atazanavir/ritonavir-based therapy on the HIV-1 cellular reservoir after 48 weeks, published in the Journal of Antimicrobial Chemotherapy.
    • 16 Feb 2017 Results (n=140) assessing the impact at 96 weeks of the dual therapy versus the triple therapy on the HIV-1 cellular reservoir presented at the 24th Conference on Retroviruses and Opportunistic Infections
    • 15 Jan 2017 Primary endpoint proportion of patients with viral load 50 copies/mL (Non inferiority efficacy (superiority on post hoc analysis) of atazanavir/ritonavir + lamivudine arm) has been met as per results published in the Journal of Antimicrobial Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top